EP1858546A4 - Modified transferrin fusion proteins - Google Patents

Modified transferrin fusion proteins

Info

Publication number
EP1858546A4
EP1858546A4 EP06736868A EP06736868A EP1858546A4 EP 1858546 A4 EP1858546 A4 EP 1858546A4 EP 06736868 A EP06736868 A EP 06736868A EP 06736868 A EP06736868 A EP 06736868A EP 1858546 A4 EP1858546 A4 EP 1858546A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
transferrin fusion
modified transferrin
modified
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06736868A
Other languages
German (de)
French (fr)
Other versions
EP1858546A2 (en
Inventor
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of EP1858546A2 publication Critical patent/EP1858546A2/en
Publication of EP1858546A4 publication Critical patent/EP1858546A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06736868A 2005-03-04 2006-03-06 Modified transferrin fusion proteins Withdrawn EP1858546A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65814005P 2005-03-04 2005-03-04
US66375705P 2005-03-22 2005-03-22
PCT/US2006/007617 WO2006096515A2 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Publications (2)

Publication Number Publication Date
EP1858546A2 EP1858546A2 (en) 2007-11-28
EP1858546A4 true EP1858546A4 (en) 2009-03-04

Family

ID=36953883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06736868A Withdrawn EP1858546A4 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Country Status (4)

Country Link
EP (1) EP1858546A4 (en)
JP (1) JP2008531059A (en)
CA (1) CA2599723A1 (en)
WO (1) WO2006096515A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
DK2049560T3 (en) 2006-07-13 2013-07-29 Novozymes Biopharma Dk As Process for the preparation of particles of proteinaceous material
WO2008012629A2 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
WO2008021412A2 (en) * 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
KR20090098880A (en) 2006-12-12 2009-09-17 바이오렉시스 파마슈티칼 코포레이션 Transferrin fusion protein libraries
GB0711424D0 (en) * 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
EP2594583A1 (en) * 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
US10457719B2 (en) 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
EP2488210A4 (en) 2009-10-12 2014-04-30 Smith Holdings Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
ES2561658T3 (en) 2009-12-16 2016-02-29 Novo Nordisk A/S GLP-1 derivatives with double acylation
EP3208282A1 (en) 2010-11-30 2017-08-23 F. Hoffmann-La Roche AG Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
RU2600440C3 (en) 2010-12-16 2021-12-10 Ново Нордиск А/С SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP2014132832A (en) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd Medicament, functional food product, stabilization method of target protein, fusion protein, nucleic acid, and recombinant
JP6124986B2 (en) 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Growth and differentiation factor (GDF) for treating diastolic heart failure
ES2952874T3 (en) 2012-03-22 2023-11-06 Novo Nordisk As GLP-1 peptide compositions and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (en) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） Tablet formulation comprising a peptide and a delivery agent
ES2853935T3 (en) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Modified Mulerian Inhibitory Substance (MIS) Proteins and Uses of The same for Treatment of Diseases
ES2945994T3 (en) 2013-03-15 2023-07-11 Gladiator Biosciences Inc Gla domains as addressing agents
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
WO2014176311A1 (en) 2013-04-23 2014-10-30 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
EP3881859B1 (en) 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
CA3151082A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
KR20170031668A (en) 2014-06-02 2017-03-21 칠드런'즈 메디컬 센터 코포레이션 Methods and compositions for immunomodulation
EP3280397A4 (en) 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
CN108368165A (en) 2015-06-24 2018-08-03 德克萨斯大学系统董事会 For treating related indication method and composition of intracranialing hemorrhage
US11753633B2 (en) 2015-08-27 2023-09-12 President And Fellows Of Harvard College Compositions and methods for treatment of pain
WO2017201428A1 (en) 2016-05-19 2017-11-23 President And Fellows Of Harvard College Methods of making gels and film using curli nanofibers
WO2019014552A1 (en) * 2017-07-14 2019-01-17 University Of Southern California Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
MA53076B1 (en) 2018-02-02 2023-11-30 Novo Nordisk As SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLATE ACID SALT AND A LUBRICANT
EP3810186B1 (en) * 2018-06-21 2022-09-28 Novo Nordisk A/S Novel compounds for treatment of obesity
US20230241171A1 (en) 2020-07-10 2023-08-03 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Also Published As

Publication number Publication date
EP1858546A2 (en) 2007-11-28
JP2008531059A (en) 2008-08-14
WO2006096515A3 (en) 2006-12-07
WO2006096515A2 (en) 2006-09-14
CA2599723A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
EP1858546A4 (en) Modified transferrin fusion proteins
IL189246A0 (en) Albumin fusion proteins
IL222924A0 (en) Albumin fusion proteins
EP1934372A4 (en) Ssb - polymerase fusion proteins
IL197580A0 (en) Albumin fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
PL1830872T3 (en) Fusion proteins
GB0426397D0 (en) Fusion proteins
IL204839A0 (en) Albumin fusion proteins
ZA200709871B (en) Interferon-IgG fusion
IL196674A0 (en) Exendin fusion proteins
EP1889908A4 (en) Anti-cd14 antibody-fused protein
IL198815A0 (en) Transferrin fusion protein libraries
ZA200801224B (en) Albumin fusion proteins
GB0514482D0 (en) Protein
EP1893635A4 (en) Anchored transferrin fusion protein libraries
GB0511861D0 (en) Proteins
GB0700759D0 (en) Novel fusion protein
GB0522113D0 (en) vWFA-domain containing proteins
GB0426399D0 (en) Fusion proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0513505D0 (en) Proteins
AU2005905300A0 (en) Fusion Protein
GB0713169D0 (en) Fusion proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071004

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090130

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/76 20060101ALI20090126BHEP

Ipc: C12P 21/02 20060101ALI20090126BHEP

Ipc: C07K 14/605 20060101ALI20090126BHEP

Ipc: A61K 38/40 20060101ALI20090126BHEP

Ipc: A61K 38/26 20060101ALI20090126BHEP

Ipc: C12N 15/63 20060101ALI20090126BHEP

Ipc: C12N 15/12 20060101AFI20090126BHEP

Ipc: C12N 15/16 20060101ALI20090126BHEP

Ipc: C12N 5/10 20060101ALI20090126BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090418